Calidi Biotherapeutics, Inc. balance sheet

At the end of fiscal 2022, Calidi Biotherapeutics, Inc. had total assets of $2.6m, total liabilities of $43.4m and shareholders' equity of −$50.4m. It held $590,000 in cash against $6.6m of debt: net debt of $6.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Calidi Biotherapeutics, Inc.: balance sheet, annual
Fiscal year	2022Dec 2022
Cash and equivalents	1
Receivables	0
Total current assets	1
Total assets	3
Accounts payable	0
Total current liabilities	43
Short-term debt	5
Total debt	7
Total liabilities	43
Shareholders' equity	−50
Non-controlling interests and other (assets − liabilities − equity)	10
Net debt (negative = net cash)	6

US$ millions unless shown otherwise. Fiscal quarters.

Calidi Biotherapeutics, Inc.: balance sheet, quarterly
Quarter	2022 Q4Dec 2022
Receivables	0
Total current assets	1
Total assets	3
Accounts payable	0
Total current liabilities	43
Short-term debt	5
Total debt	5
Total liabilities	43
Shareholders' equity	−50
Non-controlling interests and other (assets − liabilities − equity)	10
Shares outstanding	9m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Calidi Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Calidi Biotherapeutics, Inc.